MedPath

Benzatropine

Generic Name
Benzatropine
Brand Names
Cogentin
Drug Type
Small Molecule
Chemical Formula
C21H25NO
CAS Number
86-13-5
Unique Ingredient Identifier
1NHL2J4X8K
Background

Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.

Indication

用于治疗帕金森病。也用于药物引起的锥体外系疾患,口服1小时起效,肌肉或静脉注射数分钟内起效,作用持续24小时。具有抗胆碱及抗组胺作用,并有轻度局部麻醉作用。

Associated Conditions
Parkinsonism

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Phase 1
Recruiting
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
First Posted Date
2025-01-01
Last Posted Date
2025-04-17
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
400
Registration Number
NCT06754930
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder

Phase 4
Recruiting
Conditions
Functional Disorder
Interventions
Behavioral: Patient Education
Behavioral: Enhanced usual care
First Posted Date
2024-01-30
Last Posted Date
2024-01-30
Lead Sponsor
Aarhus University Hospital
Target Recruit Count
424
Registration Number
NCT06232473
Locations
🇩🇰

Research Cinic for Functional Disorders, Aarhus, Denmark

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Conditions
Main Heading (Descriptor) Terms
Interventions
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
80
Registration Number
NCT06035913
Locations
🇨🇳

Dihydroergot mesylate, Nanjing, Jiangsu, China

Mitoquinone/mitoquinol Mesylate As Oral and Safe Postexposure Prophylaxis for Covid-19

Phase 2
Recruiting
Conditions
COVID-19
SARS-CoV Infection
Interventions
First Posted Date
2023-06-02
Last Posted Date
2025-03-13
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
112
Registration Number
NCT05886816
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

Phase 1
Completed
Conditions
Antiviral Treatment
COVID-19
Respiratory Viral Infection
Interventions
First Posted Date
2022-05-19
Last Posted Date
2024-05-10
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
80
Registration Number
NCT05381454
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Phase 3
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2022-04-11
Last Posted Date
2025-02-18
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
425
Registration Number
NCT05320692
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut

Phase 2
Conditions
Advanced Melanoma
Interventions
First Posted Date
2022-03-10
Last Posted Date
2022-03-10
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
37
Registration Number
NCT05274438
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill

Not Applicable
Completed
Conditions
Cerebrovascular Diseases
Interventions
Other: blank control group
Drug: Yangxue Qingnao pill
First Posted Date
2021-07-12
Last Posted Date
2021-07-12
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
60
Registration Number
NCT04958512
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Phase 1
Completed
Conditions
Resistant or Refractory Solid Tumors
Interventions
First Posted Date
2020-12-28
Last Posted Date
2023-04-25
Lead Sponsor
Calgent Biotechnology Co., Ltd
Target Recruit Count
17
Registration Number
NCT04686383
Locations
🇺🇸

NEXT Oncology, 2829 Babcock Road Suite 300, San Antonio, Texas, United States

🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇨🇳

Tzu Chi General Hospital, Taipei Branch, New Taipei City, Taiwan

Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study

Phase 2
Conditions
Gastric Adenocarcinoma
Interventions
First Posted Date
2019-12-09
Last Posted Date
2019-12-09
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
116
Registration Number
NCT04190745
Locations
🇨🇳

Jieer Ying, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath